|
|
|
|
|
|
|
|
|
|
Do you want a say in how ovarian cancer drugs are evaluated, approved and covered? We pleased to announce that the Ovarian Cancer National Alliance is partnering with the Society of Gynecologic Oncology (SGO) on a first-of-its-kind survey for women with ovarian cancer. Your input will help the Alliance and SGO better understand the patient perspective on outcomes from clinical research–and could shape future research.
We urge all ovarian cancer survivors to click this link and complete our short survey. We want to know which endpoints are meaningful to you, and what impact various side effects have on your quality of life.
We're all used to seeing the outcomes of clinical trials reported in terms of progression-free survival, overall survival and adverse events. Those measures are the basis for whether drugs are approved by the FDA and covered by major health insurers. But what do these outcomes really mean for women with ovarian cancer?
Please help us by completing the survey and sharing it with other women with ovarian cancer. Your responses are completely anonymous. The results from this survey will be used to draft a white paper guiding future research on ovarian cancer.
If you have any questions about this survey, feel free to contact the Alliance at ocna@ovariancancer.org or (202) 331-1332.
Sent from my iPhone
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.